Standard treatments for acute myelogenous leukemia (AML) offer only a 30% survival rate at five years — an unacceptable statistic. But at UCLA Health, oncologist Caspian Oliai, MD and his team are pioneering a groundbreaking alternative: Chimeric antigen receptor iNKT cell therapy.

This innovative immunotherapy harnesses a healthy donor's immune system to fight leukemia, offering a more effective, off-the-shelf solution compared to traditional CAR T-cell therapy. With multiple mechanisms of action and the ability to be administered immediately, iNKT cell therapy could dramatically improve survival rates while reducing costs and eliminating the need for chemotherapy.

Backed by research published in leading scientific journals and supported by the state of California, UCLA Health is now ready to launch a clinical trial — but we need your support. Join us in making history by funding a life-changing therapy that could transform AML treatment for patients worldwide.

To learn more or to make a donation, visit: uclahealth.org/cancer/oliai-cure-leukemia

#LeukemiaTreatment #CancerResearch #UCLAHealth #iNKTCellTherapy #AML